Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many proteins in biology exist in more than one form. Examples include ion channels that control electrical activity in the body, metabolic enzymes, and proteins called transcription factors that help control gene expression. In immune cells, one family of transcription factors, the NFAT family, is important in cell differentiation and activation. NFATs control the expression of genes that produce signaling molecules that help co-ordinate the activities of different immune cells and defective NFAT activation is linked to a range of human diseases. Immune cells express several different NFATs, and it has proved difficult to control selectively the activity of each protein.

Professor Anant Parekh’s group in DPAG have discovered how different NFAT proteins are controlled in cells. Their new findings, published in this month’s Molecular Cell (58, 232-243), demonstrate that different patterns of signal recruit different NFAT proteins. Their results open up the possibility for drugs aimed at targeting one NFAT protein and not another, allowing for selective therapeutic control of an immune response.

Read more (Department of Physiology, Anatomy and Genetics website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.